Drugs / AbTCR-T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07168291 | Dec 2025 → Dec 2028 expected | Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma | First Affiliated Hospital Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AbTCR-T cells | “To overcome tumor immune escape driven by antigen loss, investigators designed the novel AbTCR-T cells simultaneously targeting CD19 and CD22.” NCT07168291 ↗ |
| Modality | Cell therapy | “AbTCR (anti-CD19/CD22)-T cells” NCT07168291 ↗ |
| Route | Intravenous | “AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.” NCT07168291 ↗ |